Background: Recent court decisions have thrown into question the Food and Drug Administration's rules limiting manufacturer promotion of prescription drugs for unapproved uses. We assessed how providing pro forma disclosures or more descriptive evidence context about the data supporting an off-label claim affected physicians' beliefs about drug efficacy.
Methods and results: In online and mailed surveys, we randomized national samples of board-certified, clinically active cardiologists, internists, and endocrinologists to receive 1 of 3 information scenarios about a hypothetical drug derived verbatim from excerpts on the website for Vascepa, a prescription fish oil for which Food and Drug Administration specially permitted off-label promotion after a manufacturer lawsuit. The scenarios presented information about the approved on-label indication (severe hypertriglyceridemia), off-label claim + pro forma disclaimers (suggestive but not conclusive evidence for use as an add-on to a statin for patients reaching low-density lipoprotein goal but with persistent moderate hypertriglyceridemia), and off-label claim + evidence context (eg, reports on 3 trials failing to demonstrate cardiovascular benefit of other triglyceride-lowering drugs for such patients). Among 686 respondents (48% response rate), 29% reported receiving off-label information about Vascepa (ie, use as an add-on to a statin) from the manufacturer, and 16% had prescribed it off-label for this purpose. Off-label prescribing was 5 times higher among physicians who received such off-label information (38% versus 7%, P<0.001). For the hypothetical drug, the proportion of physicians endorsing the unproven claim that the drug reduced cardiovascular risk was similar among those randomized to the on-label and off-label claim + pro forma disclaimers scenarios (35% versus 37% [95% CI, -6% to 11%]), but substantially lower among those randomized to the off-label claim + evidence context scenario (21% [95% CI, -24% to 7%]).
Conclusions: Physicians who received company information about the unapproved use of Vascepa were more likely to report prescribing it off-label. Supplementing off-label claims with evidence context improved the prescribers' knowledge and reduced enthusiasm for the unproven, off-label indication of reducing cardiovascular risk.
Keywords: fish oils; hypertriglyceridemia; prescription drugs; risk; triglyceride.
Evidence Brief: The Quality of Care Provided by Advanced Practice NursesE McCleery et al. PMID 27606392. - ReviewIn a policy paper, Newhouse and colleagues state “[o]nce the issue of comparability between APRN care and that delivered by physicians is set aside in favor of an integra …
Unwarranted Claims of Drug Efficacy in Pharmaceutical Sales Visits: Are Drugs Approved on the Basis of Surrogate Outcomes Promoted Appropriately?R Habibi et al. Br J Clin Pharmacol 83 (11), 2549-2556. PMID 28664660.Claims of efficacy made in sales visit promotions for drugs approved only on the basis of surrogate outcomes extended beyond the regulator-approved efficacy information f …
Off-label Indications for Antidepressants in Primary Care: Descriptive Study of Prescriptions From an Indication Based Electronic Prescribing SystemJ Wong et al. BMJ 356, j603. PMID 28228380.Objective To examine off-label indications for antidepressants in primary care and determine the level of scientific support for off-label prescribing.Design …
U.S. Physician Knowledge of the FDA-approved Indications and Evidence Base for Commonly Prescribed Drugs: Results of a National SurveyDT Chen et al. Pharmacoepidemiol Drug Saf 18 (11), 1094-100. PMID 19697444.These findings highlight a pressing need for more effective methods to inform physicians about the evidence base, or lack thereof, for drugs they prescribe off label.
TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDSY Handelsman et al. Endocr Pract 23 (1), 100-112. PMID 27819772. - ReviewThere is consistent evidence that triglycerides are in the causal pathway of atherosclerosis but inconsistent evidence from cardiovascular outcomes studies as to whether …